학술논문

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
Document Type
Article
Source
In Annals of Oncology January 2018 29(1):250-255
Subject
Language
ISSN
0923-7534